Local clinical draft · not published
MASLD fibrosis risk
Blood test first. Imaging when it changes the risk group.
A calculator and sequential interpretation pathway for FIB-4, ultrasound-based liver stiffness and problem-solving MRE.
01
Does the patient meet a screening indication?
CAR supports risk stratification in the target clinical population rather than indiscriminate testing.
Evidence register
What governs this draft
Dated primary sources and their role in this draft.
+
Evidence register
What governs this draft
Recommendation wording is condensed for point-of-care use. The dated primary source remains authoritative and must be rechecked before publication or institutional adoption.
CAR MASLD Part 1Detecting and Grading Hepatic Steatosis Using Ultrasound, CT, or MRIFormal CAR guidance · 2025
Detection and multimodality steatosis grading; the risk pathway does not treat steatosis grade as fibrosis stage.
Open source ↗CAR MASLD Part 2Risk Stratifying Patients With MASLDFormal CAR guideline · online 2025, 2026 issueAll FIB-4, SWE/TE and pathway-specific MRE thresholds encoded in this tool.
Open source ↗CAR MASLD Part 3SWE and MRE Program Implementation and Quality AssuranceFormal CAR guidance · 2025Programme implementation, training, funding and quality assurance.
Open source ↗